Pushing forward in sarcoma with a new TCR targeting NY-ESO-1

Rusul Al-Marayaty; Seth M. Pollack

doi:10.1016/j.xcrm.2023.101159

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1

Rusul Al-Marayaty, Seth M. Pollack^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

A phase 1 trial demonstrating the safety and efficacy of a novel NY-ESO-1-specific TCR-T cells by Pan et al.¹ is a major step forward for adoptive T cell therapy in the clinical practice of advanced soft tissue sarcomas.

Original language	English (US)
Article number	101159
Journal	Cell Reports Medicine
Volume	4
Issue number	8
DOIs	https://doi.org/10.1016/j.xcrm.2023.101159
State	Published - Aug 15 2023

Funding

S.M.P. receives research funding from Obsidian Therapeutics. He receives consulting, advisory, and speaker fees from GSK, Bayer, Deciphera, Springworks, Sensei Therapeutics, Aadi Therapeutics, and Epizyme.

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.xcrm.2023.101159

Cite this

@article{d507e199fba9407f99119c09e273be6c,

title = "Pushing forward in sarcoma with a new TCR targeting NY-ESO-1",

abstract = "A phase 1 trial demonstrating the safety and efficacy of a novel NY-ESO-1-specific TCR-T cells by Pan et al.1 is a major step forward for adoptive T cell therapy in the clinical practice of advanced soft tissue sarcomas.",

author = "Rusul Al-Marayaty and Pollack, {Seth M.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = aug,

day = "15",

doi = "10.1016/j.xcrm.2023.101159",

language = "English (US)",

volume = "4",

journal = "Cell Reports Medicine",

issn = "2666-3791",

publisher = "Cell Press",

number = "8",

}

TY - JOUR

T1 - Pushing forward in sarcoma with a new TCR targeting NY-ESO-1

AU - Al-Marayaty, Rusul

AU - Pollack, Seth M.

PY - 2023/8/15

Y1 - 2023/8/15

N2 - A phase 1 trial demonstrating the safety and efficacy of a novel NY-ESO-1-specific TCR-T cells by Pan et al.1 is a major step forward for adoptive T cell therapy in the clinical practice of advanced soft tissue sarcomas.

AB - A phase 1 trial demonstrating the safety and efficacy of a novel NY-ESO-1-specific TCR-T cells by Pan et al.1 is a major step forward for adoptive T cell therapy in the clinical practice of advanced soft tissue sarcomas.

UR - http://www.scopus.com/inward/record.url?scp=85167984457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85167984457&partnerID=8YFLogxK

U2 - 10.1016/j.xcrm.2023.101159

DO - 10.1016/j.xcrm.2023.101159

M3 - Comment/debate

C2 - 37586326

AN - SCOPUS:85167984457

SN - 2666-3791

VL - 4

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 8

M1 - 101159

ER -

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this